Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | WDR5 | P61964 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17427936 | 0.89 | MAPT (0.53) | MAPTHPGDLMNAGAAALDH1A1 | |
| SCHEMBL2117441 | 0.89 | ALOX15 (0.50) | MAPTHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL2721374 | 0.83 | LMNA (0.56) | MAPTHPGDLMNAGAAALDH1A1 | |
| SCHEMBL11425674 | 0.83 | MAPT (0.61) | MAPTHPGDLMNAGAAALDH1A1 | |
| SCHEMBL11071525 | 0.81 | MAPT (0.51) | MAPTHPGDLMNAGAAALDH1A1 | |
| SCHEMBL11126183 | 0.81 | MAPT (0.59) | MAPTHPGDLMNAGAAALDH1A1 | |
| SCHEMBL503652 | 0.81 | L3MBTL1 (0.66) | MAPTHPGDLMNAGAAALDH1A1 | |
| SCHEMBL4745488 | 0.81 | MAPT (0.47) | MAPTLMNA | |
| SCHEMBL8234368 | 0.81 | MAPT (0.59) | MAPTHPGDLMNAGAAALDH1A1 | |
| SCHEMBL105460 | 0.81 | ATF4 (0.54) | MAPTHPGDALDH1A1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | claimed |
| JP-6135989-A | — | — | None | — | — | JP | disclosed |
| US-20250134871-A1 | UPR MODULATORS TO TREAT HEARING LOSS | JACARANDA BIOSCIENCES, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-118206525-A | Aromatic ring [ d ] thiazepine ketone compound and preparation method thereof | 北京化工大学 | 2024-06-18 | — | — | CN | disclosed |
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | disclosed |
| EP-3470407-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023114451-A1 | UPR MODULATORS TO TREAT HEARING LOSS | JACARANDA BIOSCIENCES, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11234450-B2 | Preparations having a cooling effect | SYMRISE AG (DE) | 2022-02-01 | — | — | US | disclosed |
| CN-108853105-B | Cosmetic composition, pharmaceutical composition and food composition | 西姆莱斯股份公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-2931225-B1 | COOLING PREPARATIONS | SYMRISE AG (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| JP-H06135989-A | NUCLEOTIDE DERIVATIVE | TOAGOSEI CHEM IND CO LTD | 1994-05-17 | — | — | JP | disclosed |
| EP-0207690-B1 | N-SUBSTITUTED GLUTAMIC ACID DERIVATIVE AND PROCESS FOR PRODUCTION AND USE THEREOF | SUNTORY LIMITED (JP) | 1989-12-20 | — | — | EP | disclosed |
| US-4701210-A | HERBICIDES | SUNTORY LIMITED (JP) | 1987-10-20 | — | — | US | disclosed |
| EP-0207690-A1 | N-Substituted glutamic acid derivative and process for production and use thereof | SUNTORY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11234450-B2 | Preparations having a cooling effect | CRAT, CPT2, CPT1A | MAPT 22/4885HPGD 2629/4885LMNA 1034/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | MAPT 3817/4885HPGD 1311/4885LMNA 1516/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | MAPT 3817/4885HPGD 1311/4885LMNA 1516/4885 |
| US-20250134871-A1 | UPR MODULATORS TO TREAT HEARING LOSS | ATF4, XBP1, ATF1 | MAPT 1641/4885HPGD 754/4885LMNA 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.